Source link : https://newshealth.biz/health-news/evolocumab-reduced-first-cv-events-in-patients-without-prior-mi-or-stroke/
(MedPage Today) — NEW ORLEANS — Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac events (MACE) in patients with atherosclerosis or high-risk diabetes, but without a history of myocardial… Source link : https://www.medpagetoday.com/meetingcoverage/aha/118395 Author : Publish date : 2025-11-09 17:17:00 Copyright for syndicated content belongs to the linked Source.
The post Evolocumab Reduced First CV Events in Patients Without Prior MI or Stroke first appeared on News Health.
—-
Author : News Health
Publish date : 2025-11-09 17:17:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8